Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti-PD-1 Immune Checkpoint Blockade.

Pierre L TriozziElizabeth R StirlingQianqian SongBrian WestwoodMitra KooshkiM Elizabeth Forbes Beth C HolbrookKatherine L CookMartha A Alexander-MillerLance D MillerWei ZhangDavid R Soto-Pantoja

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our results suggest a glycolytic signature characterizes checkpoint inhibitor responders; consistently, both ECAR and lactate-to-pyruvate ratio were significantly associated with overall survival. Together, these findings support the use of blood bioenergetics and metabolomics as predictive biomarkers of patient response to immune checkpoint inhibitor therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
genome wide
mass spectrometry
dna damage
gene expression
case report
dna methylation
mesenchymal stem cells
copy number
cell proliferation
bone marrow
cell therapy
patient reported